<- Go Home
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Market Cap
$3.4B
Volume
384.6K
Cash and Equivalents
$306.7M
EBITDA
-$198.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$58.26
52 Week Low
$31.42
Dividend
N/A
Price / Book Value
9.58
Price / Earnings
-19.14
Price / Tangible Book Value
9.58
Enterprise Value
$3.0B
Enterprise Value / EBITDA
-15.49
Operating Income
-$200.9M
Return on Equity
40.34%
Return on Assets
-24.99
Cash and Short Term Investments
$425.1M
Debt
$75.8M
Equity
$357.9M
Revenue
N/A
Unlevered FCF
-$118.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium